In primary SGNs, Edaravone added to the medium before glutamate treatment increased MTT cell viability compared with glutamate alone. Edaravone administered after glutamate treatment yielded higher viability at the earliest tested time point, while later treatment produced no significant improvement. [1]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Edaravone Pretreatment in Primary SGNs
Cell-based study · primary SGNs [1]
Primary SGNs received Edaravone in the medium for 20 min before glutamate treatment. MTT cell viability was 75% with 500 μM Edaravone, compared with 32% with glutamate alone.
Literature-Reported Treatment Conditions
- Treatment concentration
- 250 μM, 500 μM, and 750 μM
- Exposure duration
- for 20 min before glutamate treatment
- Method
- added to the medium
- Co-treatment
- Other interventions in this design: glutamate 2 mM. Compound effect isolated by the comparison: versus glutamate-treated group.
- Reported limits
- Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Edaravone
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
2. Materials and Methods > 2.2. Primary Cultures of Rat SGNs (S13); 2. Materials and Methods > 2.3. Drug Treatment (S15, S17); 2. Materials and Methods > 2.4. Assessment of Cell Viability by MTT and Trypan Blue Staining (S20); 3. Results > 3.3. Edaravone Alleviated the Decrease of Cell Viability Caused by Glutamate (S70, S71); Figure 4 legend (S117, S118)
Cell viability was detected by MTT assay: Cell viability was detected by MTT assay; comparator: glutamate alone — 3. Results > 3.3. Edaravone Alleviated the Decrease of Cell Viability Caused by Glutamate (S70, S71); Figure 4 legend (S117)
Edaravone After Glutamate Treatment in Primary SGNs
Cell-based study · primary SGNs [1]
500 μM edaravone was added to the medium 2 h, 6 h, or 12 h after glutamate treatment. Treatment of edaravone at the time point of 2 h after glutamate achieved satisfying protection for SGNs against glutamate-induced cytotoxicity. But there was no significant improvement in cell viability when treated at later time points.
Literature-Reported Treatment Conditions
- Treatment concentration
- 500 μM
- Exposure duration
- 2 h, 6 h, or 12 h after glutamate treatment
- Method
- added to the medium
- Co-treatment
- Other interventions in this design: glutamate 2 mM. Compound effect isolated by the comparison: versus glutamate-treated group.
- Reported limits
- Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Edaravone
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
2. Materials and Methods > 2.2. Primary Cultures of Rat SGNs (S13); 2. Materials and Methods > 2.4. Assessment of Cell Viability by MTT and Trypan Blue Staining (S20); 3. Results > 3.2. Edaravone Performed Both Preventative and Therapeutic Effects against Toxicity of Glutamate (S63); 3. Results > 3.3. Edaravone Alleviated the Decrease of Cell Viability Caused by Glutamate (S74, S75, S77); Figure 3 legend (S110); Figure 5 legend (S121, S122)
Cell viability was detected by MTT assay: Cell viability was detected by MTT assay; comparator: glutamate alone — 3. Results > 3.3. Edaravone Alleviated the Decrease of Cell Viability Caused by Glutamate (S74, S75, S77); Figure 5 legend (S121)